Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Monday 19 August, 2019

AstraZeneca PLC

Directorate Change

RNS Number : 4087J
AstraZeneca PLC
19 August 2019
 

19 August 2019 07:00 BST

 

AstraZeneca appoints Michel Demaré to its Board of Directors

 

AstraZeneca today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee.

 

Leif Johansson, Chairman of AstraZeneca, said: "We are delighted to appoint Michel Demaré as a Director. He has a great deal of industrial, financial and board-level experience across a range of sectors including science and technology, that will enable him to contribute well to the work of our Board and Audit Committee."

 

Michel Demaré is a Non-Executive Director of Vodafone Group Plc and a member of the Supervisory Board of Louis Dreyfus Company Holdings BV. He is Vice-Chairman and Chairman-designate of the IMD executive business school in Lausanne, and a member of the Advisory Board of the Department of Banking and Finance at the University of Zurich.

 

Mr Demaré was Vice-Chairman of UBS Group AG from 2010 to 2019, Chairman of Syngenta and the Syngenta Foundation for Sustainable Agriculture from 2013 to 2017 and Chairman of SwissHoldings from 2013 to 2015.

 

Mr Demaré joined ABB Ltd in 2005 as Chief Financial Officer (CFO) and member of the Group Executive Committee.  For most of 2008, he acted as the interim Chief Executive Officer of ABB.  From late 2008 to 2011, he combined his role as CFO with that of President of Global Markets.

 

He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005.  Prior to that, he spent 18 years at the Dow Chemical Company, holding various treasury and risk management positions in Belgium, France, the US and Switzerland.  Between 1997 and 2002, Mr Demaré was CFO of the Global Polyolefins and Elastomers division.  He began his career as a banking officer in the multinational banking division of Continental Illinois' Belgian subsidiary.

 

Mr Demaré graduated with an MBA from the Katholieke Universiteit Leuven, Belgium, and holds a degree in applied economics from the Université Catholique de Louvain, Belgium.

 

Except as set out above, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations



Gonzalo Viña


+44 203 749 5916

Rob Skelding

Oncology

+44 203 749 5821

Rebecca Einhorn

Oncology

+1 301 518 4122

Matt Kent

BioPharmaceuticals

+44 203 749 5906

Jennifer Hursit

Other

+44 203 749 5762

Christina Malmberg Hägerstrand

Sweden

+46 8 552 53 106

Michele Meixell

US

+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen


+44 203 749 5712

Henry Wheeler

Oncology

+44 203 749 5797

Christer Gruvris

BioPharmaceuticals (cardiovascular, metabolism)

+44 203 749 5711

Nick Stone

BioPharmaceuticals (respiratory, renal)

+44 203 749 5716

Josie Afolabi

Other medicines

+44 203 749 5631

Craig Marks

Finance, fixed income

+44 7881 615 764

Jennifer Kretzmann

Corporate access, retail investors

+44 203 749 5824

US toll-free


+1 866 381 72 77

 

Adrian Kemp
Company Secretary

AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOASFUSWAFUSEFA

a d v e r t i s e m e n t